Dr. Galsky on Clinical Trials That Addressed Key Questions in Urothelial Cancer

Matthew Galsky, MD, professor of medicine (hematology and medical oncology), professor of urology, director, Genitourinary Medical Oncology, co-director, Center of Excellence for Bladder Cancer, associate director, Translational Research, The Tisch Cancer Institute, Mount Sinai, discusses clinical trials that addressed key questions in urothelial cancer.

The phase 3 IMvigor130 (NCT02807636) and KEYNOTE-361 (NCT02853305) trials addressed the question of whether chemotherapy should be given in combination with checkpoint inhibitors in the treatment of patients with metastatic urothelial carcinoma. Additionally, IMvigor130, KEYNOTE-361, as well as the phase 3 DANUBE trial (NCT02516241) answered the question of whether checkpoint inhibitors should be given alone compared with chemotherapy in this patient population.

The DANUBE trial also evaluated whether a PD-L1 inhibitor should be given in combination with a CTLA-4 inhibitor in patients with metastatic urothelial carcinoma, Galsky explains. Finally, the phase 3 JAVELIN Bladder 100 trial (NCT02603432) evaluated the utility of switch maintenance therapy with avelumab (Bavencio) in patients who derived at least stable disease with up-front chemotherapy in this patient population, Galsky concludes.